中医药通过调控肠道菌群治疗非酒精性脂肪性肝病的作用
本文综述了肠道菌群(GM)与非酒精性脂肪性肝病(NAFLD)发病机制的关系,并详细讨论多种中药活性代谢物和中药复方通过调控GM及其代谢物对NAFLD发挥治疗作用,创新性探讨中医药调控五大细菌门及其代表属的丰度以改善NAFLD发病机制,为以GM调控为重点的NAFLD防治提出新思路并为中药新药开发提供理论依据。
要点
- 中医药多成分、多靶点、多途径调控肠道菌群,契合NAFLD复杂发病机制。
- 中药活性代谢物及复方可通过调节肠道菌群及其代谢物改善NAFLD。
- 中医药调控五大细菌门及其代表属丰度可能是防治NAFLD的新靶点。
核心结论
- 中医药通过调控肠道菌群及其代谢物,可能成为NAFLD防治的新策略。
研究设计与样本
- 本文为综述,分析肠道菌群与NAFLD发病机制的关系,并讨论中医药调控肠道菌群治疗NAFLD的作用。
主要发现
- 肠道菌群与NAFLD的发生和进展密切相关,但机制复杂。
- 多种中药活性代谢物和中药复方可通过调控肠道菌群及其代谢物发挥治疗NAFLD的作用。
- 中医药可调控五大细菌门及其代表属的丰度,从而改善NAFLD的发病机制。
临床怎么用
- 临床可关注中医药通过调控肠道菌群治疗NAFLD的潜在价值,作为综合管理的一部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of non-alcoholic fatty liver disease (NAFLD) has increased and become a serious global public health problem in recent years. The currently generally used clinical treatments have disadvantages such as side effects, limitations, and poor patient compliance. Traditional Chinese medicine (TCM) has a pharmacological effect with multiple components, multiple targets, and multiple pathways, emphasizing a "holistic concept" and "differential diagnosis and treatment," which is compatible with the complex pathogenesis of GM and NAFLD. Previous studies have demonstrated a close relationship between the gut microbiome (GM) and the occurrence and progression of NAFLD. However, the mechanisms between GM and NAFLD are complex. This paper not only analyzes the relationship between the GM and the pathogenesis of NAFLD but also discusses in detail how various TCM active metabolites and Chinese herbal formulas could exert a therapeutic effect on NAFLD by regulating the GM and its metabolites. Furthermore, this paper innovatively explores how TCM regulates the abundance of five major bacterial phyla, and their representative genera, to improve the pathogenesis of NAFLD. In summary, this review article proposes innovative ideas and options for the prevention and treatment of NAFLD with focus on GM regulation, and provides a theoretical basis for the development of new drugs from traditional Chinese medicine.
引用
- Zhang Y, Li H, Jiang N, et al. The Role of Traditional Chinese Medicine in the Management of Nonalcoholic Fatty Liver Disease: Targeting Gut Microbiome. Am J Chin Med. 2025. PMID: 40926716. doi:10.1142/S0192415X25500788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。